YuceBio Secures Nearly RMB 100 Million Series C+ Financing to Advance Integrated Tumor Immunotherapy Diagnostic Platform

VCBeat (WeChat: vcbeat) has learned that Shenzhen Yuce Biological Technology Co., Ltd. (“Yuce Bio”), a high-tech biotechnology company specializing in precision immuno-oncology diagnostics and therapeutics, recently announced the completion of its C+ round financing, raising nearly RMB 100 million. The round was exclusively invested by Suizi Finance. The new funding will accelerate the company’s dual-drive strategy centered on cancer immunity, combining “clinical precision diagnostics” with “immuno-oncology drug development services,” and will help build China’s first open big-data platform for immuno-oncology diagnosis and treatment based on privacy-preserving computation and data security.

Yuce Biological Headquarters

Yuce Biological Multi-omics Experimental Platform

After years of development, Yuce Bio has remained true to its original mission, persistently exploring the underlying logic of tumor immunology-related technologies. The company has established a comprehensive multi-omics experimental platform encompassing tumor genomics, transcriptomics, plasma proteomics, and pathology/multiplex pathology. It provides Laboratory Developed Tests (LDTs) for clinical applications, including guidance on tumor immunotherapy, prediction of severe adverse reactions, and monitoring of minimal residual disease (MRD) for recurrence, alongside the regulatory approval of In Vitro Diagnostic (IVD) products. As its immune-oncology drug R&D services continue to mature, Yuce Bio will leverage this round of financing to further expand into related markets. The company is committed to helping pharmaceutical enterprises explore and validate the most effective targets and biomarkers, and to designing and implementing the most efficient clinical trial protocols. By working alongside global academic and industry partners to advance the development of precision oncology, Yuce Bio aims to benefit more cancer patients and demonstrate the social responsibility of China’s private enterprises.

Dr. Gao Zhibo, Founder and CEO of Yuce Bio

Dr. Gao Zhibo, Founder and CEO of Yuce BioHe expressed his sincere gratitude to Suizi Finance for its recognition of the company’s development. Tumor immunotherapy is currently a focal point in international anticancer research and industrialization, carrying the hope of “curing” cancer. Current research trends in immune biomarkers are generally shifting from macroscopic to microscopic levels, from static to dynamic temporal assessments, and functionally from “prediction” to “prognostication.” Adhering to its mission of “making tumor immunotherapy more effective,” Shenzhen Yuce Biological Technology Co., Ltd. remains firmly committed to deepening its expertise in the field of tumor immunology. By continuously advancing its technologies and products in both the development of precision immune diagnostic solutions for tumors and CRO services for tumor immunotherapeutic drugs, the company strives to establish itself as China’s leading brand in tumor immuno-diagnosis and treatment.

Wu Jie, Deputy General Manager of Suizi Finance

Regarding the investment in Yuce Biological Technology,Wu Jie, Deputy General Manager of Suizi FinanceIt is stated that precision medicine represents a revolutionary innovation to the existing healthcare model. Due to its complexity and refractory nature, oncology has become a frontier area in precision medicine research. Driven by the rapid advancement of gene sequencing technologies, increasingly precise and diverse diagnostic methods, clearly targeted clinical drugs, deepening biomedical analyses, and ever-evolving bio-big data and cloud computing technologies, precision medicine is leading the gradual transition from the current one-size-fits-all healthcare model to a highly personalized one, which will undoubtedly attract significant attention from market capital in the future. Shenzhen Yuce Biological Technology Co., Ltd. possesses an internationally leading platform and database for the detection and identification of tumor neoantigens, laying a solid foundation for the field of precision oncology in China.

Yuce Bio, established in June 2015, is a leading domestic provider of comprehensive solutions for tumor immuno-diagnosis and therapy. Centered on its two major research platforms—tumor genomics and the tumor microenvironment—the company has developed product lines for clinical tumor testing and sales, as well as a CRO service platform for pharmaceutical companies. Yuce Bio boasts an internationally leading platform for the detection and identification of tumor neoantigens, a multi-dimensional platform for tumor immunity detection and research, a specialized bioinformatics database for interpreting tumor immunity data, and a real-world study database focused on tumor immuno-diagnosis and treatment. Leveraging international high-standard research and production quality systems, along with an experienced management and operations team, Yuce Bio provides clinically accessible medication guidance and dynamic monitoring products for tumor patients, delivers precision medicine solutions to medical institutions and service providers, and offers high-quality companion diagnostics and therapeutic target development services to pharmaceutical companies.

Suizi Finance, established in 2014 in Qianhai, Shenzhen, adheres to the development philosophy of “Integrity, Humility, Professionalism, and Perseverance.” The firm strategically focuses on emerging national industries, particularly healthcare and the global expansion of consumer brands, positioning itself as a leading investment institution in these niche sectors across China. Its healthcare portfolio includes companies such as Akang Health, Zocdoc Medical (Zhongchao Yixue), Future Pharma, Edge Medical, Langyan Life, Heyuan Biology, Sunshine Nuohé, and Bio-Pharma. Among these, Zocdoc Medical has listed on the NASDAQ, and Sunshine Nuohé has successfully listed on the STAR Market. The annual revenue of the more than ten cross-border e-commerce enterprises in its portfolio has reached tens of billions of RMB, with total revenue projected to exceed RMB 100 billion in 2021.